"These leadership appointments mark an exciting new chapter for Gannet BioChem as an independent company," said Melanie Fan, Principal at Ampersand Capital Partners. "We are thrilled to welcome Nick and Chris to the leadership team, while continuing to collaborate with Tony in his expanded role. With their expertise and vision, this team is well-positioned to drive innovation and growth, strengthening our commitment to advancing biopharmaceutical and therapeutic products."
As the newly appointed CEO of Gannet BioChem, Nick Shackley brings over 25 years of experience in pharmaceuticals and chemical manufacturing. His leadership is defined by a strong focus on business transformation, operational efficiency, and commercial growth. Previously, he served as Senior Vice President and Chief Commercial Officer at Lupin Manufacturing Solutions, where he led sales, business development, strategic marketing, and product management. Shackley also played a pivotal role in expanding market share and implementing strategic initiatives in executive positions at Veranova, BASF, Cambrex, and Aceto Corporation. His expertise in global business strategy within life sciences manufacturing will be instrumental in driving Gannet BioChem's continued success.
Joining Nick to lead Gannet through its next chapter of growth are:
- Chris Edwards, Chief Financial Officer – An experienced financial executive, Edwards was previously CFO at Solesis and has held global finance operations roles at Syneos Health, Convatec, and Bristol-Myers Squibb.
- Dr. Tony Sander, Chief Operating Officer – A key leader at Gannet BioChem since 2003, Dr. Sander has over 30 years of experience in chemical and API manufacturing, overseeing manufacturing and site operations at the Huntsville, AL facility.
Gannet BioChem will showcase its industry-leading capabilities at DCAT 2025, where company leaders and representatives will engage with global partners to discuss growth opportunities and innovation in polyethylene glycol (PEG) reagent manufacturing.
"DCAT presents the perfect opportunity to highlight Gannet BioChem's proven expertise in developing, scaling, and manufacturing PEG reagents while connecting with industry partners," said Nick Shackley. "We are eager to share our vision for the company's continued growth and our commitment to supporting biopharmaceutical innovators worldwide."
To schedule a virtual or in-person meeting with the Gannet BioChem team, email [email protected].
About Gannet BioChem
With over 30 years of expertise, Gannet BioChem is a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents—essential components in advanced biopharmaceutical and therapeutic products. Operating from a state-of-the-art 124,000 sq. ft. FDA-inspected facility in Huntsville, Alabama, Gannet BioChem delivers end-to-end GMP production, supporting clinical and commercial therapeutics. With a highly experienced team, flexible production capabilities, and a commitment to quality, Gannet BioChem provides reliable, innovative solutions to meet the evolving needs of the global biopharmaceutical industry. For additional information, please visit GannetBioChem.com or follow us on LinkedIn.
About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit AmpersandCapital.com or follow us on LinkedIn.
SOURCE Gannet BioChem
Share this article